Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Chemed Corporation, Natera or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Chemed Corporation, Natera and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Chemed Corporation, Natera and Inc.

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Latest Health Care Providers & Services and Chemed Corporation, Natera, Inc. Stock News

As of July 31, 2026, Chemed Corporation had a $6.9 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. Chemed Corporation’s stock is NA in 2026, NA in the previous five trading days and up 27.77% in the past year.

Currently, Chemed Corporation’s price-earnings ratio is 29.1. Chemed Corporation’s trailing 12-month revenue is $2.5 billion with a 10.6% net profit margin. Year-over-year quarterly sales growth most recently was 1.6%. Analysts expect adjusted earnings to reach $25.523 per share for the current fiscal year. Chemed Corporation currently has a 0.5% dividend yield.

Currently, Natera, Inc. does not have a price-earnings ratio. Natera, Inc.’s trailing 12-month revenue is $2.5 billion with a -9.0% net profit margin. Year-over-year quarterly sales growth most recently was 38.8%. Analysts expect adjusted earnings to reach $-1.709 per share for the current fiscal year. Natera, Inc. does not currently pay a dividend.

How We Compare Chemed Corporation, Natera and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Chemed Corporation, Natera and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Chemed Corporation, Natera and Inc. Growth Grades

Company	Ticker	Growth
Chemed Corporation	CHE	B
Natera, Inc.	NTRA	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Chemed Corporation has a Growth Score of 73, which is Strong. Natera, Inc. has a Growth Score of 32, which is Weak.

The Growth Grade Winner: Chemed Corporation

As you can clearly see from the Growth Grade breakdown above, Chemed Corporation has a more attractive growth grade than Natera, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Chemed Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Chemed Corporation, Natera and Inc.’s Quality Grades

Company	Ticker	Quality
Chemed Corporation	CHE	A
Natera, Inc.	NTRA	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Chemed Corporation has a Quality Score of 98, which is Very Strong. Natera, Inc. has a Quality Score of 51, which is Average.

The Quality Grade Winner: Chemed Corporation

As you can clearly see from the Quality Grade breakdown above, Chemed Corporation has a better overall quality grade than Natera, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Chemed Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Chemed Corporation, Natera and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Chemed Corporation	CHE	B
Natera, Inc.	NTRA	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Chemed Corporation has a Earnings Estimate Score of 74, which is Positive. Natera, Inc. has a Earnings Estimate Score of 49, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Chemed Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Chemed Corporation has a better Earnings Estimate Revisions Grade than Natera, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Chemed Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Chemed Corporation, Natera and Inc. Grades

In addition to Estimate Revisions, Growth and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Chemed Corporation, Natera and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Chemed Corporation, Natera or Inc. Stock?

Overall, Chemed Corporation stock has a Growth Score of 73, Estimate Revisions Score of 74 and Quality Score of 98.

Natera, Inc. stock has a Growth Score of 32, Estimate Revisions Score of 49 and Quality Score of 51.

Comparing Chemed Corporation, Natera and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.